GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biolase Inc (NAS:BIOL) » Definitions » Piotroski F-Score

Biolase (Biolase) Piotroski F-Score : 3 (As of Apr. 30, 2024)


View and export this data going back to 1992. Start your Free Trial

What is Biolase Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Biolase has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Biolase's Piotroski F-Score or its related term are showing as below:

BIOL' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 3   Max: 5
Current: 3

During the past 13 years, the highest Piotroski F-Score of Biolase was 5. The lowest was 1. And the median was 3.


Biolase Piotroski F-Score Historical Data

The historical data trend for Biolase's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biolase Piotroski F-Score Chart

Biolase Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 2.00 5.00 1.00 3.00

Biolase Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.00 2.00 2.00 2.00 3.00

Competitive Comparison of Biolase's Piotroski F-Score

For the Medical Devices subindustry, Biolase's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biolase's Piotroski F-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biolase's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Biolase's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -5.849 + -4.868 + -4.589 + -5.326 = $-20.63 Mil.
Cash Flow from Operations was -5.658 + -3.562 + -2.588 + -2.283 = $-14.09 Mil.
Revenue was 10.467 + 14.286 + 10.921 + 13.49 = $49.16 Mil.
Gross Profit was 3.337 + 6.118 + 3.746 + 3.524 = $16.73 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(38.186 + 41.944 + 39.633 + 38.745 + 35.101) / 5 = $38.7218 Mil.
Total Assets at the begining of this year (Dec22) was $38.19 Mil.
Long-Term Debt & Capital Lease Obligation was $12.55 Mil.
Total Current Assets was $24.86 Mil.
Total Current Liabilities was $19.66 Mil.
Net Income was -4.776 + -5.611 + -8.387 + -9.861 = $-28.64 Mil.

Revenue was 10.166 + 12.235 + 12.01 + 14.051 = $48.46 Mil.
Gross Profit was 4.729 + 5.141 + 2.445 + 3.596 = $15.91 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(55.284 + 50.242 + 50.854 + 42.865 + 38.186) / 5 = $47.4862 Mil.
Total Assets at the begining of last year (Dec21) was $55.28 Mil.
Long-Term Debt & Capital Lease Obligation was $14.35 Mil.
Total Current Assets was $28.96 Mil.
Total Current Liabilities was $17.81 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Biolase's current Net Income (TTM) was -20.63. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Biolase's current Cash Flow from Operations (TTM) was -14.09. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-20.632/38.186
=-0.54030273

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-28.635/55.284
=-0.5179618

Biolase's return on assets of this year was -0.54030273. Biolase's return on assets of last year was -0.5179618. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Biolase's current Net Income (TTM) was -20.63. Biolase's current Cash Flow from Operations (TTM) was -14.09. ==> -14.09 > -20.63 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=12.554/38.7218
=0.32421013

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=14.35/47.4862
=0.30219306

Biolase's gearing of this year was 0.32421013. Biolase's gearing of last year was 0.30219306. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=24.863/19.663
=1.26445609

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=28.959/17.807
=1.62627057

Biolase's current ratio of this year was 1.26445609. Biolase's current ratio of last year was 1.62627057. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Biolase's number of shares in issue this year was 3.416. Biolase's number of shares in issue last year was 0.078. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=16.725/49.164
=0.34018794

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=15.911/48.462
=0.3283191

Biolase's gross margin of this year was 0.34018794. Biolase's gross margin of last year was 0.3283191. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=49.164/38.186
=1.28748756

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=48.462/55.284
=0.87660082

Biolase's asset turnover of this year was 1.28748756. Biolase's asset turnover of last year was 0.87660082. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+0+0+1+1
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Biolase has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Biolase  (NAS:BIOL) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Biolase Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Biolase's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Biolase (Biolase) Business Description

Traded in Other Exchanges
Address
27042 Towne Centre Drive, Suite 270, Lake Forest, CA, USA, 92610
Biolase Inc is a US-based medical device company. It develops, manufactures, markets, and sells laser systems in dentistry and medicine. The company also markets, sells and distributes dental imaging equipment, including cone beam digital x-rays and CAD/CAM intraoral scanners. It offers two categories of laser system products: Waterlase (all-tissue) systems and Diode (soft-tissue) systems which allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The majority of the company's revenue comes from the United States.
Executives
Goldman Sachs & Co. Llc 10 percent owner 200 WEST STREET, NEW YORK NY 10282
Goldman Sachs Group Inc 10 percent owner 200 WEST STREET, NEW YORK NY 10282
Lord Jonathan T Md director 500 WEST MAIN ST., LOUISVILLE KY 40202
Jennifer Bright officer: Chief Financial Officer 27042 TOWNE CENTRE DRIVE,, SUITE 270, FOOTHILL RANCH CA 92610
Steven Sandor officer: Chief Operating Officer 27042 TOWNE CENTRE DRIVE,, SUITE 270, FOOTHILL RANCH CA 92610
Jess Roper director 5555 OBERLIN DRIVE, SAN DIEGO CA 92121
Kenneth P. Yale director 27042 TOWN CENTRE DRIVE, SUITE 270, FOOTHILL RANCH CA 92610
John R Beaver director, officer: President & CEO C/O STERLING CHEMICALS INC, 1200 SMITH STREET, HOUSTON TX 77002
Kathleen T Oloughlin director 27042 TOWN CENTRE DRIVE, SUITE 270, FOOTHILL RANCH CA 92610
Somerman Martha J. Dds, Phd director 27042 TOWN CENTRE DRIVE, SUITE 270, FOOTHILL RANCH CA 92610
Summerhays Carol Gomez Dds director 27042 TOWN CENTRE DRIVE, SUITE 270, FOOTHILL RANCH CA 92610
Family Foundation Schuler 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Larry N Feinberg 10 percent owner C/O ORACLE PARTNERS L P, 200 GREENWICH AVENUE, GREENWICH CT 06830
Jack W Schuler 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Michael Ditolla director 3299 CAMBRIDGE AVE, BRONX NY 10463